Trials / Terminated
TerminatedNCT02227784
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 366 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the ACCENTUATE study is to evaluate whether the study drug known as evacetrapib is effective in treating participants with high cholesterol and atherosclerotic cardiovascular disease (ASCVD) and/or diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evacetrapib | Administered orally |
| DRUG | Atorvastatin | Administered orally |
| DRUG | Ezetimibe | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2014-08-28
- Last updated
- 2019-10-08
- Results posted
- 2018-03-22
Locations
64 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT02227784. Inclusion in this directory is not an endorsement.